Saba Rouhani
Saba Rouhani
Assistant Professor of Epidemiology
-
Professional overview
-
Dr. Saba Rouhani is an Assistant Professor in the Department of Epidemiology at GPH. She conducts research in social epidemiology, policy evaluation, and overdose prevention.
Prior to joining NYU Dr. Rouhani worked as research faculty in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health. She also completed a fellowship funded by the National Institutes of Health/National Institute on Drug Abuse. Her research has been published in the International Journal of Drug Policy, Drug and Alcohol Dependence, the Journal of Urban Health, and the American Journal of Public Health and Preventive Medicine.
Dr. Rouhani received her PhD in global disease epidemiology and control from the Johns Hopkins Bloomberg School of Public Health. She holds an MSc in the control of infectious diseases from the London School of Hygiene and Tropical Medicine, and a BSc in medical microbiology from the University of Edinburgh.
-
Education
-
PhD Global Disease Epidemiology & Control, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAMS Control of Infectious Diseases, The London School of Hygiene & Tropical Medicine, London, United KingdomBS Medical Microbiology, University of Edinburgh, Edinburgh, United Kingdom
-
Honors and awards
-
Drug Dependency Epidemiology Training (T32) Fellowship, National Institute of Drug Abuse, National Institutes of Health (2018)The R. Bradley Sack Family Scholarship Award, Johns Hopkins Bloomberg School of Public Health (2016)Global Health Established Field Placement Scholarship, Johns Hopkins Bloomberg School of Public Health (2014)Save the Children Program Management Award, Save the Children International (2012)Royal Society of Tropical Medicine and Hygiene Award for Best Poster Presentation of Research in Progress (2012)
-
Publications
Publications
Norovirus infection and acquired immunity in 8 countries : Results from the MAL-ED study
AbstractRouhani, S. (n.d.).Publication year
2016Journal title
Clinical Infectious DiseasesVolume
62Issue
10Page(s)
1210-1217AbstractBackground. Norovirus is an important cause of childhood diarrhea. We present data from a longitudinal, multicountry study describing norovirus epidemiology during the first 2 years of life. Methods. A birth cohort of 1457 children across 8 countries contributed 7077 diarrheal stools for norovirus testing. A subset of 199 children contributed additional asymptomatic samples (2307) and diarrheal stools (770), which were used to derive incidence rates and evaluate evidence for acquired immunity. Results. Across sites, 89% of children experienced at least 1 norovirus infection before 24 months, and 22.7% of all diarrheal stools were norovirus positive. Severity of norovirus-positive diarrhea was comparable to other enteropathogens, with the exception of rotavirus. Incidence of genogroup II (GII) infection was higher than genogroup I and peaked at 6-11 months across sites. Undernutrition was a risk factor for symptomatic norovirus infection, with an increase in 1 standard deviation of length-for-age z score associated with a 17% reduction (odds ratio, 0.83 [95% confidence interval,. 72-.97]; P =. 011) in the odds of experiencing diarrhea when norovirus was present, after accounting for genogroup, rotavirus vaccine, and age. Evidence of acquired immunity was observed among GII infections only: Children with prior GII infection were found to have a 27% reduction in the hazard of subsequent infection (hazard ratio, 0.727; P =. 010). Conclusions. The high prevalence of norovirus across 8 sites in highly variable epidemiologic settings and demonstration of protective immunity for GII infections provide support for investment in vaccine development.